Vaxcyte, Inc.
PCVX
$30.68
-$1.62-5.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 49.20% | 64.24% | 62.93% | 47.31% | 48.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.87% | 57.94% | -17.55% | 23.80% | 75.54% |
| Operating Income | -47.87% | -57.94% | 17.55% | -23.80% | -75.54% |
| Income Before Tax | -29.42% | -48.09% | 24.18% | -11.29% | -88.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.42% | -48.09% | 24.18% | -11.29% | -88.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.42% | -48.09% | 24.18% | -11.29% | -88.33% |
| EBIT | -47.87% | -57.94% | 17.55% | -23.80% | -75.54% |
| EBITDA | -47.29% | -56.72% | 18.63% | -23.09% | -75.50% |
| EPS Basic | -11.56% | -21.90% | 42.50% | 8.53% | -57.50% |
| Normalized Basic EPS | -11.56% | -21.91% | 42.52% | 8.51% | -57.48% |
| EPS Diluted | -11.56% | -21.90% | 42.50% | 8.53% | -57.50% |
| Normalized Diluted EPS | -11.56% | -21.91% | 42.52% | 8.51% | -57.48% |
| Average Basic Shares Outstanding | 16.01% | 21.49% | 31.87% | 21.66% | 19.58% |
| Average Diluted Shares Outstanding | 16.01% | 21.49% | 31.87% | 21.66% | 19.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |